Aegis Capital Cuts Rosetta Genomics (ROSG) to Hold; Diagnostics Tests Continue to Lag
Tweet Send to a Friend
Aegis Capital downgrades Rosetta Genomics (Nasdaq: ROSG) from Buy to Hold, while slashing its price target from $10 down to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
